HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on BioXcel Therapeutics (NASDAQ:BTAI) and maintained an $11 price target for the company's stock.
November 15, 2023 | 11:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioXcel Therapeutics has been given a Buy rating and an $11 price target by HC Wainwright & Co. analyst Raghuram Selvaraju.
The reiteration of a Buy rating and the maintenance of an $11 price target by a reputable analyst could instill confidence in investors and positively influence the stock price in the short term. The direct mention of the company and the specific price target suggest a high relevance and importance to the company's stock. The confidence score is high due to the clear and direct nature of the analyst's rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100